Why invest in Infensa Bioscience?
- Infensa Bioscience assets represent potential transformative therapies for patients with significant unmet medical need in stroke, heart attack and heart transplantation
- Minimal capital required to achieve patient and financial impact, with clear near-term inflection point (i.e., successful Phase I clinical trial for heart transplantation)
- Heart transplantation provides a fast route to a revenue-generating market and allows time for strategic targeting of bigger markets with millions of patients
- Series A funding will take company past first major value inflection point (successful Phase I trial for heart transplantation) and poised for clinical trials in the first major market (heart attack)
- ESIC status provides major tax incentives for sophisticated investors
Placeholder for Gantt chart showing timelines for development
Advantages of investing in an ESIC
- Infensa Bioscience will qualify as an Early Stage Innovation Company (ESIC)
- ESIC provides the following tax incentives for eligible sophisticated investors*:
- A 20% tax offset (capped at $200K)
- No CGT for capital gains on shares held for 1–10 years
- Market value cost base from the 10th year onwards